Summary of Study ST000398
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000311. The data can be accessed directly via it's Project DOI: 10.21228/M8G020 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST000398 |
| Study Title | Metabolic profiling of maternal urine can aid clinical management of Gestational Diabetes Mellitus (GDM) |
| Study Type | Search for non-treated and treated GDM biomarkers in urine |
| Study Summary | NMR metabolomics study of maternal urine of 1) GDM women at the time of diagnosis and before treatment, to define the urine metabolic profile of untreated GDM, and of 2) GDM women treated using diet control alone or with the addition of insulin, to identify treatment-resistant and treatment-responsive metabolic pathways and, hence, evaluate treatment efficacy, and 3) GDM treatment prediction at the time of diagnosis, with the aim of finding potential predictive markers of future treatment requirements based on each individual metabotype. |
| Institute | University of Aveiro |
| Department | CICECO-Department of Chemistry |
| Last Name | Gil |
| First Name | Ana |
| Address | CICECO-Department of Chemistry, University of Aveiro |
| agil@ua.pt | |
| Phone | none |
| Submit Date | 2016-04-20 |
| Num Groups | 5 |
| Total Subjects | 98 |
| Analysis Type Detail | NMR |
| Release Date | 2016-06-18 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
| Project ID: | PR000311 |
| Project DOI: | doi: 10.21228/M8G020 |
| Project Title: | Urine metabolomics for the study of Gestational Diabetes Mellitus |
| Project Summary: | A urine NMR metabolomics study using a variable selection methodology to reduce uninformative variability enables a metabolic signature of gestational diabetes mellitus (GDM) to be identified at the time of diagnosis. This signature comprises relevant changes in 12 NMR metabolites/resonances and qualitative variations in a number of additional metabolites. |
| Institute: | University of Aveiro |
| Department: | CICECO-Department of Chemistry |
| Last Name: | Gil |
| First Name: | Ana |
| Address: | CICECO-Department of Chemistry, University of Aveiro |
| Email: | agil@ua.pt |
| Phone: | none |
Subject:
| Subject ID: | SU000419 |
| Subject Type: | Human |
| Subject Species: | Homo sapiens |
| Taxonomy ID: | 9606 |
| Age Or Age Range: | 18-41 years |
| Gender: | Female |
| Human Race: | Caucasian |
| Species Group: | Human |
Factors:
Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)
| mb_sample_id | local_sample_id | group ID |
|---|---|---|
| SA019107 | PU81_09_1_1 | Control group 1 | Treatment duration:NA |
| SA019108 | PU848_06_1_1 | Control group 1 | Treatment duration:NA |
| SA019109 | PU3T9_11_31gw_1_1 | Control group 1 | Treatment duration:NA |
| SA019110 | PU640_10_22gw_1_1 | Control group 1 | Treatment duration:NA |
| SA019111 | PU2T2_10_16gw_1_1 | Control group 1 | Treatment duration:NA |
| SA019112 | PU895_06_1_1 | Control group 1 | Treatment duration:NA |
| SA019113 | PU3T25_11_32gw_1_1 | Control group 2 | Treatment duration:NA |
| SA019114 | PU3T27_11_38gw_2_1 | Control group 2 | Treatment duration:NA |
| SA019115 | PU3T26_11_33gw_1_1 | Control group 2 | Treatment duration:NA |
| SA019116 | PU3T24_11_38gw_1_1 | Control group 2 | Treatment duration:NA |
| SA019117 | PU3T22_11_37gw_1_1 | Control group 2 | Treatment duration:NA |
| SA019118 | PU3T17_11_37gw_1_1 | Control group 2 | Treatment duration:NA |
| SA019119 | PU3T11_11_39gw_1_1 | Control group 2 | Treatment duration:NA |
| SA019120 | PU3T18_11_39gw_1_1 | Control group 2 | Treatment duration:NA |
| SA019121 | PU3T1_12_1_1 | Control group 2 | Treatment duration:NA |
| SA019122 | PU3T21_11_37gw_1_1 | Control group 2 | Treatment duration:NA |
| SA019123 | PU3T30_11_35gw_1_1 | Control group 2 | Treatment duration:NA |
| SA019124 | PU3T43_11_1_1 | Control group 2 | Treatment duration:NA |
| SA019125 | PU3T8_11_29gw_1_1 | Control group 2 | Treatment duration:NA |
| SA019126 | PU3T9_11_31gw_2_1 | Control group 2 | Treatment duration:NA |
| SA019127 | PU895_06_2_1 | Control group 2 | Treatment duration:NA |
| SA019128 | PU1129_09_1_1 | Control group 2 | Treatment duration:NA |
| SA019129 | PU3T5_11_32gw_1_1 | Control group 2 | Treatment duration:NA |
| SA019130 | PU3T51_11_2_1 | Control group 2 | Treatment duration:NA |
| SA019131 | PU1253_09_26gw_1_1 | Control group 2 | Treatment duration:NA |
| SA019132 | PU3T3_11_39gw_1_1 | Control group 2 | Treatment duration:NA |
| SA019133 | PU3T10_11_35gw_1_1 | Control group 2 | Treatment duration:NA |
| SA019134 | PU3T34_11_31gw_1_1 | Control group 2 | Treatment duration:NA |
| SA019135 | PU3T39_11_1_1 | Control group 2 | Treatment duration:NA |
| SA019136 | PU3T2_11_32gw_1_1 | Control group 2 | Treatment duration:NA |
| SA019137 | PU3T11_10_26gw_1_1 | Control group 2 | Treatment duration:NA |
| SA019138 | PU3T32_11_32gw_1_1 | Control group 2 | Treatment duration:NA |
| SA019139 | PU3T8_12_1_1 | Control group 2 | Treatment duration:NA |
| SA019140 | PU1288_09_1_1 | Control group 2 | Treatment duration:NA |
| SA019141 | PU3T7_12_1_1 | Control group 2 | Treatment duration:NA |
| SA019142 | PU3T6_10_32gw_1_1 | Control group 2 | Treatment duration:NA |
| SA019143 | PU3T46_11_1_1 | Diet treated-GDM | Treatment duration:11 |
| SA019144 | PU3T40_11_1_1 | Diet treated-GDM | Treatment duration:11 |
| SA019145 | PU2T10_11_1_1 | Diet treated-GDM | Treatment duration:12 |
| SA019146 | PU3T4_12_1_1 | Diet treated-GDM | Treatment duration:13 |
| SA019147 | PUsc3410_1_1 | Diet treated-GDM | Treatment duration:2 |
| SA019148 | PU3T2_12_1_1 | Diet treated-GDM | Treatment duration:2 |
| SA019149 | PU3T5_10_1_1 | Diet treated-GDM | Treatment duration:2 |
| SA019150 | PUsc2310_1_1 | Diet treated-GDM | Treatment duration:2 |
| SA019151 | PUsc3010_1_1 | Diet treated-GDM | Treatment duration:2 |
| SA019152 | PUsc2610_1_1 | Diet treated-GDM | Treatment duration:2 |
| SA019153 | PU3T14_11_1_1 | Diet treated-GDM | Treatment duration:3 |
| SA019154 | PU2T811_1_1 | Diet treated-GDM | Treatment duration:3 |
| SA019155 | PU2T11_11_3_1 | Diet treated-GDM | Treatment duration:3 |
| SA019156 | PUsc2210_1_1 | Diet treated-GDM | Treatment duration:3 |
| SA019157 | PUsc2710_3_1 | Diet treated-GDM | Treatment duration:3 |
| SA019158 | PUsc1010_3_1 | Diet treated-GDM | Treatment duration:3 |
| SA019159 | PUsc2410_1_1 | Diet treated-GDM | Treatment duration:3 |
| SA019160 | PUsc3610_1_1 | Diet treated-GDM | Treatment duration:4 |
| SA019161 | PUsc2110_1_1 | Diet treated-GDM | Treatment duration:4 |
| SA019162 | PU668_09_1_1 | Diet treated-GDM | Treatment duration:4 |
| SA019163 | PUsc310_2_1 | Diet treated-GDM | Treatment duration:5 |
| SA019164 | PUsc410_2_1 | Diet treated-GDM | Treatment duration:5 |
| SA019165 | PUsc1_11_1_1 | Diet treated-GDM | Treatment duration:6 |
| SA019166 | PUsc2010_1_1 | Diet treated-GDM | Treatment duration:7 |
| SA019167 | PUsc710_3_1 | Diet treated-GDM | Treatment duration:7 |
| SA019168 | PUsc3210_1_1 | Diet treated-GDM | Treatment duration:7 |
| SA019169 | PUsc2810_1_1 | Diet treated-GDM | Treatment duration:7 |
| SA019170 | PU3T44_11_1_1 | Diet treated-GDM | Treatment duration:9 |
| SA019171 | PUsc110_2_1 | Insulin treated-GDM | Treatment duration:12 |
| SA019172 | PU3T41_11 | Insulin treated-GDM | Treatment duration:14 |
| SA019173 | PUsc910_2_1 | Insulin treated-GDM | Treatment duration:22 |
| SA019174 | PUsc2510_1_1 | Insulin treated-GDM | Treatment duration:3 |
| SA019175 | PU3T38_11_1_1 | Insulin treated-GDM | Treatment duration:6 |
| SA019176 | PUsc210_2_1 | Insulin treated-GDM | Treatment duration:6 |
| SA019177 | PU1106_09_Ins_2T_1_1 | Insulin treated-GDM | Treatment duration:7 |
| SA019178 | PUsc610_2_1 | Insulin treated-GDM | Treatment duration:9 |
| SA019179 | U_Dx4_15_1_1 | Non treated-GDM, Diet-requiring | Treatment duration:NA |
| SA019180 | U_Dx27_15_1_1 | Non treated-GDM, Diet-requiring | Treatment duration:NA |
| SA019181 | U_Dx5_15_1_1 | Non treated-GDM, Diet-requiring | Treatment duration:NA |
| SA019182 | PU_HDD9_11_1_1 | Non treated-GDM, Diet-requiring | Treatment duration:NA |
| SA019183 | U_Dx11_15_1_1 | Non treated-GDM, Diet-requiring | Treatment duration:NA |
| SA019184 | PU_HDD8_11_1_1 | Non treated-GDM, Diet-requiring | Treatment duration:NA |
| SA019185 | PU_HDD5_12_1_1 | Non treated-GDM, Diet-requiring | Treatment duration:NA |
| SA019186 | PU_HDD3_11_1_1 | Non treated-GDM, Diet-requiring | Treatment duration:NA |
| SA019187 | PU_HDD3_12_1_1 | Non treated-GDM, Diet-requiring | Treatment duration:NA |
| SA019188 | U_Dx26_15_1_1 | Non treated-GDM, Diet-requiring | Treatment duration:NA |
| SA019189 | U_Dx13_15_1_1 | Non treated-GDM, Diet-requiring | Treatment duration:NA |
| SA019190 | U_Dx25_15_1_1 | Non treated-GDM, Diet-requiring | Treatment duration:NA |
| SA019191 | PU_HDD5_11_1_1 | Non treated-GDM, Insulin-requiring | Treatment duration:NA |
| SA019192 | U_Dx23_15_1_1 | Non treated-GDM, Insulin-requiring | Treatment duration:NA |
| SA019193 | PU_HDD10_11_1_1 | Non treated-GDM, Insulin-requiring | Treatment duration:NA |
| SA019194 | PU_HDD1_11_1_1 | Non treated-GDM, Insulin-requiring | Treatment duration:NA |
| SA019195 | PU_HDD2_12_1_1 | Non treated-GDM, Insulin-requiring | Treatment duration:NA |
| SA019196 | PU_HDD1_12_1_1 | Non treated-GDM, Insulin-requiring | Treatment duration:NA |
| Showing results 1 to 90 of 90 |
Collection:
| Collection ID: | CO000413 |
| Collection Summary: | Urine samples were collected at routine medical appointments and diabetes counselling appointments, for independent groups of women in their 2nd and 3rd trimesters of pregnancy. Samples were collected under ethical approval of the Hospital Center of Coimbra (Refs.18/04 and 29/09) and informed consents were obtained from each woman. |
| Sample Type: | Urine |
| Collection Location: | Maternity Bissaya Barreto, Coimbra, Portugal |
| Collection Time: | Non-fasting, during morning |
| Volumeoramount Collected: | 50 mL |
| Storage Conditions: | -80ºC |
| Additives: | No |
Treatment:
| Treatment ID: | TR000433 |
| Treatment Summary: | Subjects were treated with diet or insulin |
| Treatment Compound: | Insulin |
Sample Preparation:
| Sampleprep ID: | SP000426 |
| Sampleprep Summary: | Before analysis, samples were thawed and 800 μL were centrifuged (4500g, 5 min). Then, 60 μL of 1.5 M phosphate buffer pH 7 in D2O, 0.1% Na+/3-trimethylsilyl-propionate (TSP) were added to 540 μL of supernatant, followed by pH readjustment to 7.00±0.02 with KOD (4 M) or DCl (4 M). The mixture was centrifuged (4500 g, 5 min) and 550 μL transferred to 5 mm NMR tubes. |
Analysis:
| Analysis ID: | AN000635 |
| Laboratory Name: | CICECO metabolomics group |
| Analysis Type: | NMR |
| Analysis Protocol File: | noesypr1d |
| Software Version: | Topspin 3.2 |
| Num Factors: | 21 |
NMR:
| NMR ID: | NM000067 |
| Analysis ID: | AN000635 |
| Instrument Name: | Bruker Avance DRX 500 |
| Instrument Type: | FT-NMR |
| NMR Experiment Type: | 1D 1H |
| NMR Comments: | Standard experiment (noesypr1d) |
| Field Frequency Lock: | Deuterium |
| Spectrometer Frequency: | 500 MHz |
| NMR Probe: | BBI |
| NMR Solvent: | D2O+H2O |
| NMR Tube Size: | 5 mm |
| Shimming Method: | Automatic |
| Pulse Sequence: | noesypr1d |
| Water Suppression: | presaturation |
| Receiver Gain: | 32 |
| Chemical Shift Ref Cpd: | TSP |
| Temperature: | 300 K |
| Number Of Scans: | 128 |
| Dummy Scans: | 4 |
| Acquisition Time: | 3.25 s |
| Relaxation Delay: | 32 |
| Spectral Width: | 20.16 ppm |
| Num Data Points Acquired: | 64 k |
| Real Data Points: | 64 k |
| Line Broadening: | 0.3 Hz |
| Baseline Correction Method: | manual |
| Chemical Shift Ref Std: | TSP (0.0 ppm) |
| Binned Increment: | full resolution |
| Binned Data Excluded Range: | 4.60-5.05 ppm |
